ABSCI CORP Payments to Acquire Debt Securities, Available-for-sale
ABSCI CORP (ABSI) reported Payments to Acquire Debt Securities, Available-for-sale of $22.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- ABSCI CORP payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $3.96M, a 77.76% decline year-over-year.
- ABSCI CORP payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $18.61M, a 53.62% decline year-over-year.
- ABSCI CORP payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was -$15.01M, a 156.35% decline year-over-year.
- ABSCI CORP payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $76.93M, a 172.41% increase year-over-year.
- ABSCI CORP payments to acquire debt securities, available-for-sale for fiscal 2025 was $119.87M, a 35.59% decline from fiscal 2024.
- ABSCI CORP payments to acquire debt securities, available-for-sale for fiscal 2024 was $186.11M, a 26.31% increase from fiscal 2023.
- ABSCI CORP payments to acquire debt securities, available-for-sale for fiscal 2023 was $147.35M, a 35.69% increase from fiscal 2022.
- ABSCI CORP payments to acquire debt securities, available-for-sale for fiscal 2022 was $108.59M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $22.57M 10-Q · filed 2026-08-11 | $7.57M derived: sum of 3 quarters · filed 2026-08-11 | $84.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $18.61M 10-Q · filed 2026-05-07 | $3.61M derived: sum of 2 quarters · filed 2026-05-07 | $80.54M derived: sum of 3 quarters · filed 2026-05-07 | $98.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$15.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $61.93M derived: sum of 2 quarters · filed 2026-03-24 | $79.73M derived: sum of 3 quarters · filed 2026-08-11 | $119.87M 10-K · filed 2026-03-24 |
| 2025-09-30 | $76.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $94.74M derived: sum of 2 quarters · filed 2026-08-11 | $134.87M 10-Q · filed 2025-11-12 | $161.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $17.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $57.94M 10-Q · filed 2026-08-11 | $84.57M derived: sum of 3 quarters · filed 2026-08-11 | $112.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $40.13M 10-Q · filed 2026-05-07 | $66.76M derived: sum of 2 quarters · filed 2026-05-07 | $95.00M derived: sum of 3 quarters · filed 2026-05-07 | $128.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $26.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $54.87M derived: sum of 2 quarters · filed 2026-03-24 | $88.78M derived: sum of 3 quarters · filed 2026-03-24 | $186.11M 10-K · filed 2026-03-24 |
| 2024-09-30 | $28.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $62.15M derived: sum of 2 quarters · filed 2025-11-12 | $159.48M 10-Q · filed 2025-11-12 | $184.63M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $33.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $131.24M 10-Q · filed 2025-08-12 | $156.39M derived: sum of 3 quarters · filed 2025-08-12 | $185.96M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $97.33M 10-Q · filed 2025-05-13 | $122.48M derived: sum of 2 quarters · filed 2025-05-13 | $152.05M derived: sum of 3 quarters · filed 2025-05-13 | $175.60M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $25.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $54.72M derived: sum of 2 quarters · filed 2025-03-18 | $78.27M derived: sum of 3 quarters · filed 2025-03-18 | $147.35M 10-K · filed 2025-03-18 |
| 2023-09-30 | $29.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $53.12M derived: sum of 2 quarters · filed 2024-11-12 | $122.20M 10-Q · filed 2024-11-12 | $156.93M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $23.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $92.63M 10-Q · filed 2024-08-14 | $127.36M derived: sum of 3 quarters · filed 2024-08-14 | $201.22M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $69.07M 10-Q · filed 2024-05-14 | $103.81M derived: sum of 2 quarters · filed 2024-05-14 | $177.66M derived: sum of 3 quarters · filed 2024-05-14 | $177.66M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $34.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $108.59M derived: sum of 2 quarters · filed 2024-03-21 | $108.59M derived: sum of 3 quarters · filed 2024-03-21 | $108.59M 10-K · filed 2024-03-21 |
| 2022-09-30 | $73.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $73.85M derived: sum of 2 quarters · filed 2023-11-14 | $73.85M 10-Q · filed 2023-11-14 | $73.85M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |